Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID

Beth E. Meyerson, Keith G. Bentele, Danielle M. Russell, Benjamin R. Brady, Missy Downer, Roberto C. Garcia, Irene Garnett, Rebecca Lutz, Arlene Mahoney, Savannah Samorano, Christina Arredondo, Honey J. Andres, Haley Coles, Alma B Granillo

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Objective To understand patient experience of federal regulatory changes governing methadone and buprenorphine (MOUD) access in Arizona during the COVID-19 pandemic. Methods This community-based participatory and action research study involved one-hour, audiorecorded field interviews conducted with 131 people who used methadone and/or buprenorphine to address opioid use disorder at some point during COVID (January 1, 2020- March 31, 2021) in Arizona. Transcribed data were analyzed using a priori codes focused on federally recommended flexibilities governing MOUD access. Data were quantitated to investigate associations with COVID risk and services access. Results Telehealth was reported by 71.0% of participants, but the majority were required to come to the clinic to attend video appointments with an offsite provider. Risk for severe COVID outcomes was reported by 40.5% of the sample. Thirty-eight percent of the sample and 39.7% of methadone patients were required to be at the clinic daily to get medication and 47.6% were at high risk for COVID severe outcomes. About half (54.2%) of methadone patients indicated that some form of multi-day take home dosing was offered at their clinic, and 45.8% were offered an extra day or two of multi-day doses; but no participants received the federally allowed 14- or 28-day methadone take-home doses for unstable and stable patients respectively. All participants expressed that daily clinic visits interrupted their work and home lives and desired more take-home dosing and home delivery options. Conclusions MOUD patients in Arizona were not offered many of the federally allowed flexibilities for access that were designed to reduce their need to be at the clinic. To understand the impact of these recommended treatment changes in Arizona, and other states where they were not well implemented, federal and state regulators must mandate these changes and support MOUD providers to implement them.

Original languageEnglish (US)
Article numbere0274094
JournalPloS one
Issue number10 October
StatePublished - Oct 2022

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID'. Together they form a unique fingerprint.

Cite this